CytoSorbents Reports Impressive Growth Metrics for 2024
Fourth quarter product revenue growth estimated at 22% to 25% year-over-year
Fourth quarter gross margin estimated to improve to approximately 70%
Management to host in-person investor meetings during a key healthcare conference
PRINCETON, N.J. — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of critical conditions through advanced blood purification technologies, has shared its preliminary, unaudited financial results for the fourth quarter and full year of 2024. The numbers indicate significant growth trajectories, particularly noteworthy for stakeholders and potential investors.
Financial Highlights of 2024
CytoSorbents reported that fourth-quarter product revenue, excluding grant income, is estimated to be between $9.0 million and $9.2 million. This marks an impressive growth of 22% to 25% compared to $7.35 million during the same period in 2023.
Annual Revenue Performance
For the full year, the product revenue is anticipated to be in the range of $35.4 million to $35.6 million, which translates to an approximate growth of 14% from $31.1 million recorded in 2023. These figures reflect the company's resilience and strength in its core international market segments.
Improvement in Gross Margin
The company is also projected to see its fourth-quarter gross margin improve significantly to around 70%, a notable rise from the previous quarter's 61% and slightly lower than the fourth quarter of 2023, which was 72%. This improvement is attributed to successful adjustments following previous manufacturing challenges.
Strategic Developments and Future Outlook
In December 2024, CytoSorbents initiated a rights offering, concluding on January 10, 2025. As they aim for further market penetration, substantial reviews by the U.S. Food and Drug Administration (FDA) and Health Canada are ongoing for their investigational medical device, DrugSorb™-ATR. This device is designed to mitigate perioperative bleeding in patients undergoing coronary artery bypass graft (CABG) surgery while on Brilinta (ticagrelor) therapy.
Company Insights from Leadership
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, expressed satisfaction with the company’s performance, stating, “Our strong year-over-year growth underscores the critical role that CytoSorb plays in managing a variety of severe conditions in the medical field.” He highlighted that the combination of revenue increase and improved gross margins set the stage for operational efficiencies as the organization prepares to enter the North American market with DrugSorb-ATR.
Upcoming Investor Engagement Opportunities
The management team is set to engage with investors during the 43rd Annual J.P. Morgan Healthcare Conference. This prominent event, occurring in January, will be hosted in San Francisco. Meetings will be coordinated through ICR Healthcare on behalf of the company, facilitating discussions with key executives.
Future Products and Innovations
CytoSorbents is committed to advancing its range of unique blood purification technologies, which utilize biocompatible polymer beads to extract harmful substances from the blood. This technology has broad applications, especially in critical care settings where life-threatening conditions like sepsis and severe trauma are prevalent.
The flagship product, CytoSorb, is approved for use in the European Union and has been deployed in over 76 countries, demonstrating its efficacy with over a quarter-million procedures performed worldwide. CytoSorb has also received FDA Emergency Use Authorization for alleviating inflammatory responses in critically ill COVID-19 patients.
Conclusion
With numerous FDA designations and a range of innovative products under development, CytoSorbents Corporation is poised for further growth in 2024. The success of the rights offering, alongside promising regulatory reviews, will likely enhance their operational capabilities and market presence significantly.
Frequently Asked Questions
1. What were CytoSorbents' growth figures for the fourth quarter of 2024?
CytoSorbents reported estimated product revenue growth of 22% to 25% for the fourth quarter, with revenue between $9.0 million and $9.2 million.
2. How does the company's gross margin affect its financial health?
The gross margin is expected to improve to approximately 70%, signaling enhanced profitability and efficiency in operations.
3. What new products are on the horizon for CytoSorbents?
Cytosorbents is actively developing DrugSorb™-ATR, targeting the reduction of perioperative bleeding for patients on certain antithrombotic drugs.
4. How does CytoSorb work in medical treatments?
CytoSorb utilizes biocompatible polymer beads to absorb toxins and contaminants from blood, aiding patients in critical conditions.
5. How can investors engage with CytoSorbents management?
Investors can engage during the J.P. Morgan Healthcare Conference, with meetings arranged through ICR Healthcare.
